GLP-1 Care Through Perimenopause and Menopause

Does a GLP-1 still work in perimenopause and after menopause?

Yes. In the SURMOUNT-1 trial, women on tirzepatide lost about 23% of their body weight whether they were perimenopausal or postmenopausal, against 3% on placebo⁵. What changes with each stage is not whether the medicine works but what you are treating it against: where fat settles, how fast muscle and bone are lost, and whether you still need contraception.

The midlife metabolic shift is real

Many women feel that their body changed almost overnight in their forties, and the science backs that up. Across the menopause transition, body composition shifts toward more fat and less lean mass, and weight tends to creep up in a way that pre-menopausal habits no longer control². Falling and fluctuating estrogen is part of why fat redistributes toward the abdomen, raising metabolic risk even when the number on the scale moves only modestly⁴. The same transition thins hair on its own timetable, which is why midlife shedding that starts after a GLP-1 is so easily misattributed — telling the two apart changes what you do about it.

The best measurements come from SWAN, a long-running US study that scanned women's body composition every year. At the start of the transition, the rate of fat gain doubled and lean mass began to fall, and both trends continued until about two years after the final period before leveling off². A separate four-year study that measured belly fat by CT found that only the women who went through menopause gained the deeper visceral fat around the organs, and their fat burning dropped by about 32%⁶.

What changes at each stage, and what the trials show

For comparison, premenopausal women in the same trial lost about 26% on tirzepatide⁵. The gap between the stages is small next to the gap between drug and placebo.

What do the trials actually say about menopause stage?

The figures in the table come from a 2025 analysis of women in three tirzepatide trials, SURMOUNT-1, -3 and -4, who were sorted after the fact into premenopause, perimenopause and postmenopause⁵. In SURMOUNT-1, 97% to 98% of women in every stage lost at least 5% of their body weight on tirzepatide, compared with 29% to 33% on placebo, and the other two trials showed similar results. Among women who started with a BMI under 35, 30% to 52% moved into the low-belly-fat range by waist-to-height ratio.

Two cautions keep those numbers honest. The analysis was done after the trials ended rather than planned in advance, and most of its authors work for Eli Lilly, which makes tirzepatide. Neither makes the results wrong, but both are reasons to treat the stage comparison as reassuring rather than settled.

For semaglutide, the STEP 1 obesity trial found a mean weight reduction of about 15%, with a substantial share of participants being midlife women³. It was not broken down by menopause stage in the same way. The closest data is a Mayo Clinic study of postmenopausal women prescribed semaglutide: the 16 women also on hormone therapy lost an average of 16% of their body weight at 12 months, against 12% for the 90 who were not⁷. It is small and retrospective, so it shows that hormone therapy did not blunt semaglutide, not that it reliably adds to it.

Where GLP-1 medicines fit

GLP-1 receptor agonists act on appetite and insulin response rather than on estrogen, so they address the metabolic side of the transition, not the hormonal one directly. They will not stop hot flashes, night sweats or vaginal dryness. For many women, the most sensible framing is GLP-1 care as one tool alongside — not instead of — a conversation about menopausal hormone therapy, sleep, strength training and cardiovascular risk¹. That last point deserves its own scrutiny: the landmark trial behind the "GLP-1s reduce cardiovascular risk" claim enrolled a population that skewed heavily male, which our guide to heart disease risk in women unpacks — worth reading given that cardiovascular risk itself rises sharply once estrogen's protective effect fades after menopause.

If you are weighing hormone therapy too, our guide to whether HRT makes you gain weight walks through the trials, and why fat moves to your middle in midlife explains the shift these medicines are often prescribed against.

What changed in the FDA's hormone therapy warnings?

On November 10, 2025, the FDA asked the makers of menopausal hormone therapy to remove the heart disease, breast cancer and probable dementia statements from the boxed warning at the top of the label⁸, and on February 12, 2026 it approved the first six updated labels⁹. The endometrial cancer warning stays in the box for systemic estrogen-alone products, and the other risks are still described in each label's warnings section⁸. If you have had hormone-sensitive breast cancer, the change does not reopen the question on its own: ACOG still advises trying nonhormonal treatments first¹², and our guide to GLP-1 and breast cancer history covers that situation. Our guide to HRT and weight gain sets out the before-and-after in a table.

The change does not alter the weight answer, and it does not make hormone therapy right for everyone. It does mean many women are revisiting HRT at the same time as they consider a GLP-1, which is why the two conversations increasingly happen together.

Choosing a provider in this stage of life

Because perimenopause layers hormonal symptoms on top of metabolic ones, oversight and labs matter more here, not less. A provider that checks thyroid and metabolic markers, understands where you are in the transition, and can coordinate with the clinician managing any hormone therapy is worth more than the cheapest sticker price. That is why our ranking weights clinical oversight and hormonal suitability heavily — see the full Luna Fit Score methodology, and our reviews of hormone- and longevity-aware programs. If you want the provider question answered directly rather than the evidence behind it, we score every program on those midlife-specific factors on our menopause ranking, and the overall women's ranking scores the same providers on all six factors at once.

A quick way to judge a program is its intake form. A careful one asks when your last period was, whether you use hormone therapy and in what form, what birth control you rely on, whether you take thyroid or other morning medicines, and whether you have had a bone density scan. If the form asks only for your height, weight and goal weight, the program is not set up for the questions this stage raises. A menopause-focused clinic works the other way round, and our review of Midi Health, where hormone therapy, labs and a GLP-1 can come from the same nurse practitioner, shows what that looks like in practice, including its per-visit billing. Our checklist for judging a program before you pay covers the rest.

If you would rather start with someone local, here is how to find a menopause specialist near you, and why testosterone is rarely the weight answer it is marketed as.

Comparing a menopause practice with a weight program

The care fee, appointment bill and prescription cost can be separate purchases. Our reviews of Evernow's membership and visit options and Maven Clinic's hormone and GLP-1 care explain those distinctions. Read the current service and renewal terms before comparing either with a medication-inclusive weight program. A broad women's-health service is useful only if it provides the clinician access and follow-up you need.

Do you still need birth control in perimenopause?

Usually, yes. GLP-1 medicines are not appropriate during pregnancy, and pregnancy is still possible in perimenopause because ovulation becomes unpredictable rather than absent. That matters more with tirzepatide: the Zepbound label says the medicine can make the pill less reliable, and tells women on oral birth control to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase¹⁰. Our guide to GLP-1s and birth control covers the options.

The same slower stomach emptying can affect the absorption of other oral medications, including oral estradiol, and the effect is largest after the first dose and each increase¹⁰. If hot flashes come back or you notice spotting after a dose change, mention it. A patch or gel avoids the stomach entirely.

Pill or shot, and what it costs at each stage

Your stage can tip the choice of form. The Wegovy pill has to be taken on an empty stomach with up to 4 ounces of water and a 30-minute wait before food, drink or other medicines, which is a daily juggle if you also take thyroid medicine or oral estradiol in the morning. Foundayo, the other GLP-1 pill, can be taken at any time, with or without food. A weekly shot avoids the daily timing question altogether. Our Foundayo vs Wegovy pill guide compares the two pills for women in detail.

Cost changes with age too. In October 2026, brand GLP-1s bought without insurance started at $149 a month for the two pills and rose with the dose; our guide to TrumpRx, LillyDirect and NovoCare prices lists every dose. For women on Medicare, which in practice means most women well past menopause, the Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 and covers Wegovy, Foundayo and the Zepbound KwikPen for a $50 monthly copayment if you meet its BMI and health criteria¹¹. If you qualify, that is far below any self-pay price.

The cautions that matter

One midlife-specific consequence deserves naming before you start: fast weight loss in this window costs lean mass at an age when bone and muscle are already under pressure, which our guide to muscle loss on a GLP-1 in midlife covers along with what to ask a program about it. Bone follows a similar pattern — a randomized trial in adults at elevated fracture risk found measurably lower bone density in the semaglutide group at one year, which our guide to GLP-1 and bone density covers in full, and it matters more here than at other ages because postmenopausal bone loss is already the steepest of any life stage. Postmenopausal breast cancer risk is another place this transition changes the calculus, covered in our guide to GLP-1 and breast cancer history. If you would rather read the programs than the evidence, every one we score is written up individually in our provider reviews.

For women already using hormones, our guide to GLP-1 medicines with HRT explains the limits of the combination evidence and why oral progesterone and unexpected bleeding need their own review.

What to ask your clinician at each stage

• In perimenopause: Which birth control works with this medicine, and what happens to my cycle as I lose weight?
• Around your final period: Are my symptoms hormonal, metabolic or both, and which should we treat first?
• After menopause: Should I have a bone density scan before starting, and how will we protect muscle?
• At any stage, if you take hormone therapy: Is my estrogen oral or transdermal, and should anything change while I start or raise the dose?

As always, this is educational information, not medical advice — decisions in this stage of life are best made with a clinician who can see your whole picture¹.

Midlife care programs can use different formulations and billing terms. Our Kina review examines those distinctions; the Joi weight-care review explains its ongoing prices and minimum commitment.